Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Status:
Recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects on patients with metastatic melanoma of
taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same
type of agent continuously. Researchers want to see if the two ways of giving this type of
treatment work equally well in extending the life of patients with melanoma, or not.